Hahn, N. M., Zahurak, M., Kaimakliotis, H. Z., Masterson, T. A., Adra, N., Chen, D. Y., Kutikov, A., Geynisman, D. M., Smelser, W. W., Reimers, M. A., Anderson, C. B., Stein, M. N., Baras, A. S., Colocho, G., Schwartz, D. G., McConkey, D. J., Patel, S. H., Rahim, B. G., O'Donnell, M. A., Kates, M. (2025). A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.667